

Meningococcal (A, C, W, Y) Vaccine

Vaccine Description	<ul style="list-style-type: none"> • Brands: Menveo® and MenQuadfi® • Inactivated, bacterial polysaccharide conjugate • See package insert
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: IM (Menveo® and MenQuadfi®) - (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy) • See package insert
Indications	<ul style="list-style-type: none"> • U.S. military basic trainees • Deploying personnel per CCMD guidance • Children at the 11-12 year of age visit or at subsequent visit • People who might be infected during an outbreak of certain types of meningococcal disease • Anyone traveling to, or living in, a part of the world where meningococcal disease is common, such as sub-Saharan Africa • Anyone who has a non-functioning spleen or whose spleen has been removed (asplenia) • Anyone who has terminal complement component deficiency (an immune system disorder) • Persons receiving a complement inhibitor (e.g., eulizumab; [Soliris]) • People at occupational risk • College freshmen, especially those who live in dormitories • People with HIV infection
Administration Schedule	<ul style="list-style-type: none"> • Single dose for most adults • Two doses, 2 months apart, for adults at high risk; e.g., HIV infection, asplenia, complement component deficiency, or traveling or residing in countries in which the disease is common • Menveo®: Single dose vial is licensed for 10-55 years, 2 vial presentation is licensed for 2mo-55 years. • MenQuadfi® is licensed for 2 years and older • Individuals 56 years or older who are recommended meningococcal vaccination can receive either meningococcal conjugate vaccine (ACIP)
Booster (Menveo® and MenQuadFi®)	<ul style="list-style-type: none"> • Menveo® and MenQuadfi®: • A booster dose is recommended for people 19 through 21 years of age who are at risk (above) or first-year college students living in residence halls or a military recruit, if previous dose given before 16 years of age • People with persistent risk need booster every 5 years for as long as risk is present (this includes those with risk due to travel, persistent complement component deficiency, or functional or anatomic asplenia)

Continued on Next Page

Meningococcal (A, C, W, Y) Vaccine

(Continued)

Contraindications	<ul style="list-style-type: none">• Serious allergic reaction to prior dose or vaccine component• Moderate or severe illness (temporary waiver)• Menveo: severe allergic reaction to any diphtheria toxoid or CRM₁₉₇ containing vaccine.• MenQuadfi: severe allergic reaction to a tetanus toxoid-containing vaccine
Special Considerations	<ul style="list-style-type: none">• Menveo® and MenQuadfi® have not been widely studied in pregnant or lactating women and should be given only if clearly indicated.• Persons aged ≥56 years who are recommended meningococcal vaccination because they are at increased risk for meningococcal disease can receive either MenACWY conjugate vaccine. This includes:<ul style="list-style-type: none">◦ Meningococcal vaccine-naïve persons ≥56 years who require only a single dose of vaccine (e.g. travelers and persons at risk as a result of a community outbreak)◦ Persons who are recommended for revaccination or for whom multiple doses are anticipated (e.g., persons with asplenia, HIV, and microbiologists)• **Penbraya (MenABCWY) is licensed as a 2-dose series given 6 months apart, for individuals aged 10-25 years. Pfizer's MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit for:<ul style="list-style-type: none">◦ Healthy individuals age 16 through 23 years (routine schedule) when shared clinical decision-making (SCDM) favors administration of MenB vaccination (requires order from privileged provider).◦ Individuals age 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines◦ The MenB component of Penbraya is the MenB vaccine Trumenba. As Trumenba and Bexsero are not interchangeable, a primary series and any future MenB booster doses must be of the same brand.• See Storage and Handling Section

VIS: <http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html>

Standing Orders: www.health.mil/standingorders

Pregnancy registry for Menactra®: 1-800-822-2463 (Sanofi Pasteur); Pregnancy registry for Menveo®: 1-877-311-8972 (Novartis); also notify DHA- IHD

Additional education may be found at www.health.mil/meningococcal